Other Clinical Trial - Efficacy & Safety of Dexamethasone Prevention for

Status Not yet recruiting

Clinical Trial Summary

This prospective, randomized, controlled clinical trial will evaluate the effect and security of dexamethasone prevention for Patients of Ovarian Hyperstimulation Syndrome.

Clinical Trial Description

Ovarian hyperstimulation syndrome (OHSS) is a iatrogenic complication of ovarian stimulation,which in its severe form is associated with significant morbidity and can be life threatening. It is characterized by cystic enlargement of the ovaries and rapid fluid shifts from the intravascular compartment to the third space. It is thought that increased vascular permeability is the pivotal mechanism of OHSS pathophysiology. The administration of human chorionic gonadotrophin results in the release of vasoactive substance such as vascular endothelial growth factor that causes vasodilation and leakage of fluids. Glucocorticoids and their synthetic derivatives have an inhibitory effect on the VEGF gene expression in vascular smooth muscle cells. By reducing leukocytic infiltration and the release of inflammatory mediator, inhibiting vasodilation and preventing increases in vascular permeability, these agents can dampen the inflammatory response and prevent edema formation ,thus offering a potential therapeutic intervention for OHSS. Investigators have observed more than a hundred patients in clinical practice that low-dose dexamethasone has prevention action for patients in IVF cycles at high risk of OHSS. This clinical trial is designed to evaluate the effect and security of dexamethasone prevention for patients of Ovarian Hyperstimulation Syndrome. There are two groups: bromocriptine group, dexamethasone group .After followed-up for 7 days , Clinical OHSS parameters will be collected at oocyte retrieval and at the 4rd d and 6th d of treatment . ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Ovarian Hyperstimulation Syndrome
Syndrome

Clinical Trial Details

NCT number	NCT02846493
Study type	Interventional
Source	Sun Yat-sen University
Contact	Haitao Zeng, M.D. & Ph.D.
Phone	020-38048012
Email	zenghaitao@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	August 2016
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00617864` - The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome	N/A
Withdrawn	`NCT01979341` - The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes	N/A
Completed	`NCT01427335` - Calcium for Prevention of Ovarian Hyperstimulation Syndrome	Phase 3
Completed	`NCT01014104` - Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome	Phase 1/Phase 2
Recruiting	`NCT00119925` - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"	N/A
Completed	`NCT06333691` - Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin	N/A
Terminated	`NCT01714648` - Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?	Phase 4
Completed	`NCT01500863` - Endometrial Receptivity After GnRH Agonist Triggering	Phase 4
Recruiting	`NCT00417144` - Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients	Phase 4
Completed	`NCT03876145` - The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome	N/A
Completed	`NCT05588635` - Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
Not yet recruiting	`NCT02392520` - Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)	N/A
Completed	`NCT00665041` - Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome	Phase 2
Completed	`NCT00835523` - Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist	N/A
Active, not recruiting	`NCT05638529` - Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome	Phase 4
Not yet recruiting	`NCT03071172` - Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET	Phase 3
Recruiting	`NCT02084940` - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF	N/A
Completed	`NCT01815138` - Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS	Phase 4
Completed	`NCT00867659` - The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors	N/A
Completed	`NCT01569256` - Ovarian Hyperstimulation Syndrome and Cabergoline	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms